Childhood leukemia-lymphoma. Heterogeneity of phenotypes and prognoses.
Results are reported on 724 children and adolescents with acute leukemia-lymphoma. One hundred patients had immunologic marker analysis that defined the major phenotypic groups, i.e., T-cell, B-cell (Burkitt), myeloid, and the most frequent form, non-T, non-T "common" or "undifferentiated" acute leukemia. Pre-T, pre-B, and "null" leukemias are included in the latter group. Response to therapy and survival was best in non-T, non-B acute lymphocytic leukemia, intermediate in T-cell disease, and worst in B-cell (Burkitt) disease. Additional factors resulting in decreased survival include elevated peripheral leukocyte count, presence of enlarged nodes, less depression of hemoglobin and platelets, and age greater than 7 years (all associated with 'lymphomatous" disease). Other factors resulting in decreased survival include age under 3 years and depression of serum immunoglobulins. Definition of the heterogeneity of childhood leukemia-lymphoma dictates differing forms of therapy for the various types of these diseases.
D000293:Adolescent; D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D007945:Leukemia, Lymphoid / Q000097:blood / Q000175:diagnosis; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D008223:Lymphoma / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis
D000951:Antigens, Neoplasm